COVID-19: clinical issues from the Japan Surgical Society
Masaki Mori(Kyushu University), Yuko Kitagawa(Keio University), Yohei Yamada(Harvard University), Yoh Asahi(Hokkaido University), Taizo Hibi(Kumamoto University), Minoru Ōno(University of Tokyo Hospital), Kenji Yuzawa(National Hospital Organization Mito Medical Center), Hiroaki Nagano(Kyushu University), Seigo Nakamura(SHOWA Medical University), Michiaki Unno(Tohoku University), Akinobu Taketomi(Hokkaido University), Tatsuo Kuroda(National Center For Child Health and Development), Yoshio Takesue(Hyogo Medical University), Tatsuya Orimo(Hokkaido University), Norihiko Ikeda(Tokyo Medical University), Takashi Kuwayama(SHOWA Medical University)
Cited by 44
Related Papers
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial
|The Lancet|2022|1.6k
Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05)
|Japanese Journal of Clinical Oncology|2018|534
Randomized clinical trial of adjuvant gemcitabine chemotherapy <i>versus</i> observation in resected bile duct cancer
|British journal of surgery|2018|401
Clinical practice guidelines for the management of biliary tract cancers 2015: the 2<sup>nd</sup> English edition
|Journal of Hepato-Biliary-Pancreatic Sciences|2015|300